Finally, we determined whether there is a cross-talk between the NFκB pathway and the PI3-kinase/AKT pathway in PEL cells and whether combined targeting of these pathways with sub-optimal doses of inhibitors would induce a more potent apoptosis in PEL cells. The gene discussed is AKT1; the disease is primary effusion lymphoma.